Trials / Completed
CompletedNCT02184689
Efficacy and Safety of Fexinidazole in Children at Least 6 Years Old and Weighing Over 20 kg With Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open Study, plug-in to the Pivotal Study
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 125 (actual)
- Sponsor
- Drugs for Neglected Diseases · Academic / Other
- Sex
- All
- Age
- 6 Years – 14 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the study is to assess the efficacy and safety of an oral regimen of fexinidazole (once daily for 10 days) in the treatment of stage 1 and stage 2 T.b. gambiense sleeping sickness in children at least 6 years old and over 20 kg bodyweight.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | fexinidazole |
Timeline
- Start date
- 2014-05-03
- Primary completion
- 2016-12-14
- Completion
- 2017-06-27
- First posted
- 2014-07-09
- Last updated
- 2020-06-24
Locations
1 site across 1 country: Democratic Republic of the Congo
Source: ClinicalTrials.gov record NCT02184689. Inclusion in this directory is not an endorsement.